Evidence map›Paper›PMID 38198042›Full record

ArticleAdvances in therapy2024

Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy.

Arun K Mankan, Nagender Mankan, Begona de Las Heras, Shakti H Ramkissoon, Olga Bodriagova, Laura Vidal, Enrique Grande, Kamal S Saini

Abstract readComment
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Sex differences in disease: sex chromosome and immunity.Journal of translational medicine · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Arun K MankanFortrea Inc., 8, Moore Drive, Durham, NC, 27709, USA. arun.mankan@fortrea.com.ORCID 0000-0002-9398-9713
Nagender MankanNorthwest Georgia Oncology Centers, Roswell, GA, USA.
Begona de Las HerasFortrea Inc., 8, Moore Drive, Durham, NC, 27709, USA.
Shakti H RamkissoonLabcorp Oncology, Durham, NC, USA.
Olga BodriagovaFortrea Inc., 8, Moore Drive, Durham, NC, 27709, USA.
Laura VidalFortrea Inc., 8, Moore Drive, Durham, NC, 27709, USA.
Enrique GrandeMD Anderson Cancer Center Madrid, Madrid, Spain.
Kamal S SainiFortrea Inc., 8, Moore Drive, Durham, NC, 27709, USA. Kamalveer.saini@fortrea.com.ORCID 0000-0001-6301-3309
Cambridge University Hospitals NHS Foundation Trust · GBMD Anderson Cancer Center Madrid · ESNational College of Arts · PKWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICI) have emerged as an important therapeutic approach for patients with cancers including bladder cancer (BC). This commentary describes a recent study that demonstrated that the loss of Y chromosome (LOY) and/or loss of specific genes on Y chromosome confers an aggressive phenotype to BC because of T cell dysfunction resulting in CD8

Indexed as

Chromosomes, Human, YUrinary Bladder NeoplasmsHistone DemethylasesHumansImmunotherapyMinor Histocompatibility AntigensPhenotypePrognosisHistone DemethylasesKDM5D protein, humanMinor Histocompatibility AntigensBladder cancerImmune checkpoint inhibitorsImmunotherapyLoss of Y chromosomeT cell exhaustion

Identifiers

PMID38198042
OpenAlexW4390700257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.